Factors associated with phosphodiesterase type 5 inhibitor treatment satisfactions: results of patient interrogation

Cimen S., Demir O., ASLAN G., ESEN A. A.

AGING MALE, vol.12, pp.58-61, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12
  • Publication Date: 2009
  • Doi Number: 10.1080/13685530903033232
  • Journal Name: AGING MALE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.58-61
  • Keywords: Discontinuation, drop-out, erectile dysfunction, patient interrogation, PDE5 inhibitor, treatment, MALE ERECTILE DYSFUNCTION, SILDENAFIL, UPDATE, EPIDEMIOLOGY
  • Dokuz Eylül University Affiliated: Yes


Introduction. Phosphodiesterase type 5 (PDE5) inhibitor therapy is an efficacious means of treatment for erectile dysfunction (ED). PDE5 inhibitors supply penile erection by inhibiting the hydrolysis of cGMP and therefore relaxing the corpus cavernosum. In this study, retrospective evaluation of those patients who were admitted to our clinic with the complaint of ED and who were recommended on PDE5 inhibitor treatment in terms of follow-up results and patient satisfaction were aimed.